n.a. (SNTS)

0.00
NASDAQ
Prev Close 0.00
Day Low/High 0.00 / 0.00
52 Wk Low/High 0.00 / 0.00
Exchange NASDAQ
Shares Outstanding 67.14M
Div & Yield N.A. (N.A)
Santarus Reports Fourth Quarter And Full Year 2012 Financial Results

Santarus Reports Fourth Quarter And Full Year 2012 Financial Results

Santarus, Inc. (NASDAQ: SNTS), today reported financial and operating results for the quarter and year ended December 31, 2012.

Santarus To Present At March Investment Conferences

Santarus To Present At March Investment Conferences

Santarus, Inc. (NASDAQ: SNTS) today announced that Gerald T.

Santarus To Hold Fourth Quarter And Full Year 2012 Financial Results Conference Call On March 4

Santarus To Hold Fourth Quarter And Full Year 2012 Financial Results Conference Call On March 4

Santarus, Inc. (NASDAQ: SNTS) today announced that it will release fourth quarter 2012 financial results after market close on Monday, March 4, 2013.

Santarus Announces Commercial Launch Of UCERIS (budesonide) Extended Release Tablets

Santarus Announces Commercial Launch Of UCERIS (budesonide) Extended Release Tablets

Santarus, Inc. (NASDAQ: SNTS) announced today the U.

Santarus To Present At Leerink Swann Global Healthcare Conference

Santarus To Present At Leerink Swann Global Healthcare Conference

Santarus, Inc. (NASDAQ: SNTS) today announced that Debra P.

Santarus And VeroScience Announce Publication Of Positive Data From Pivotal CYCLOSET® (bromocriptine Mesylate) Efficacy Study

Santarus And VeroScience Announce Publication Of Positive Data From Pivotal CYCLOSET® (bromocriptine Mesylate) Efficacy Study

Santarus, Inc. (NASDAQ: SNTS) and VeroScience, LLC today announced publication of positive data from a double-blind, placebo-controlled, multi-center pivotal study with CYCLOSET ® (bromocriptine mesylate) ...

Cramer's 'Mad Money' Recap: The Bullish Facts

Cramer's 'Mad Money' Recap: The Bullish Facts

It's hard to be a bear in this market over the long run, Cramer said.

Rules of the Game: Healthy Fundamentals

These three medical stocks are moving up in heavier-than-normal volume. 

Staying the Course

I'm not messing around with trading-index ETFs this year.

Over the Cliff We Go

Will market players continue to provide bids while waiting for the politicians to act like adults?

5 Stocks Insiders are Buying This Week

5 Stocks Insiders are Buying This Week

Insiders usually buy their own shares for one reason: They think the stock is a bargain and has tremendous upside.

Top Insider Trades: LMCA, ST, SNTS, BEAV

Top Insider Trades: LMCA, ST, SNTS, BEAV

The top 10 open-market insider purchases and sales filed at the SEC Wednesday.

Too Soon to Be an Outright Bear

If forced to hazard a prediction, I would say that the market will consolidate or decline tomorrow.

Stocks Under $5: Discount Drug Name

Stocks Under $5: Discount Drug Name

Portfolio manager David Peltier analyzes a volatile, low-dollar drug stock.

Santarus And VeroScience Announce Publication Of New Analysis Of CYCLOSET (bromocriptine Mesylate) Cardiovascular Data In The Journal Of The American Heart Association

Santarus And VeroScience Announce Publication Of New Analysis Of CYCLOSET (bromocriptine Mesylate) Cardiovascular Data In The Journal Of The American Heart Association

Santarus, Inc. (NASDAQ: SNTS) and VeroScience, LLC today announced that new analyses of cardiovascular endpoint data from a previously disclosed 52-week, randomized safety study with CYCLOSET ® ...

5 Under-$10 Stocks Set to Trade Higher in November

5 Under-$10 Stocks Set to Trade Higher in November

You don't even have to catch the entire move in lower-priced stocks such as these to make outsized returns when trading.

Santarus Reports Third Quarter 2012 Financial Results

Santarus Reports Third Quarter 2012 Financial Results

Santarus, Inc. (NASDAQ: SNTS) today reported financial and operating results for the quarter ended September 30, 2012.

Santarus And Pharming Announce Positive Top-Line Phase III Results For RUCONEST In Acute Hereditary Angioedema

Santarus And Pharming Announce Positive Top-Line Phase III Results For RUCONEST In Acute Hereditary Angioedema

Santarus, Inc. (NASDAQ: SNTS) and Pharming Group NV (NYSE Euronext: PHARM) today announced that their pivotal Phase III clinical study to evaluate the safety and efficacy of the investigational drug...

Santarus To Present At November Investor Conferences

Santarus To Present At November Investor Conferences

Santarus, Inc. (NASDAQ: SNTS) today announced that Gerald T.

Santarus To Hold Third Quarter 2012 Financial Results Conference Call On November 7

Santarus To Hold Third Quarter 2012 Financial Results Conference Call On November 7

Santarus, Inc. (NASDAQ: SNTS) today announced that it will release third quarter 2012 financial results after market close on Wednesday, November 7, 2012.

Santarus Announces Publication Of Results From UCERIS Pivotal Study In Gastroenterology

Santarus Announces Publication Of Results From UCERIS Pivotal Study In Gastroenterology

Santarus, Inc. (NASDAQ: SNTS) today announced that results from its CORE I clinical study, one of two of the company’s pivotal Phase III clinical studies with UCERIS ™ (budesonide) in ulcerative colitis,...

Santarus Announces Positive Top-Line Phase III Results For Rifamycin SV MMX In Travelers’ Diarrhea

Santarus Announces Positive Top-Line Phase III Results For Rifamycin SV MMX In Travelers’ Diarrhea

Santarus, Inc. (NASDAQ: SNTS) today announced that its Phase III clinical study to evaluate the safety and efficacy of the investigational drug, rifamycin SV MMX ®, met the primary endpoint of reducing time to...

Santarus Announces Appellate Court Reversal In Part Of ZEGERID Invalidity Decision

Santarus Announces Appellate Court Reversal In Part Of ZEGERID Invalidity Decision

Santarus, Inc. (NASDAQ: SNTS) today announced that the U.

Santarus To Present At September Investment Conferences

Santarus To Present At September Investment Conferences

Santarus, Inc. (NASDAQ:SNTS) today announced that Gerald T.

Santarus Inc. Stock Upgraded (SNTS)

Santarus Inc. Stock Upgraded (SNTS)

Santarus (Nasdaq:SNTS) has been upgraded by TheStreet Ratings from a hold to buy.

Santarus Announces FDA Extension Of UCERIS New Drug Application Target Action Date To January 16, 2013

Santarus Announces FDA Extension Of UCERIS New Drug Application Target Action Date To January 16, 2013

Santarus, Inc. (NASDAQ: SNTS) today announced that the U.

Santarus' CEO Discusses Q2 2012 Results - Earnings Call Transcript

Santarus' CEO Discusses Q2 2012 Results - Earnings Call Transcript

Santarus' CEO Discusses Q2 2012 Results - Earnings Call Transcript

Santarus Reports Second Quarter 2012 Financial Results

Santarus Reports Second Quarter 2012 Financial Results

Santarus, Inc. (NASDAQ: SNTS), a specialty biopharmaceutical company, today reported financial and operating results for the quarter ended June 30, 2012.

Santarus To Hold Second Quarter 2012 Financial Results Conference Call On August 7

Santarus To Hold Second Quarter 2012 Financial Results Conference Call On August 7

Santarus, Inc. (NASDAQ: SNTS) today announced that it will release second quarter 2012 financial results after market close on Tuesday, August 7, 2012.